Skip to main content Go body Go Menu

SK Bioscience, To Be Listed on KOSPI in March… “400 Billion Won in Facility Investment”

NSP NEWS AGENCY, By soon ki Lee Journali, 2021-02-24 09:47 END7
#SKBioscience #KOSPI #March

(Seoul=NSP News Agency) soon ki Lee Journalist = SK Bioscience is preparing to be listed on KOSPI in March. For the approximate schedule, starting with the demand forecast on March 4th to 5th, public offerings will be proceeded for general investors from 9th to 10th.

The total number of shares in the public offering is 22.95 million, of which 459,000 shares, or 20 percent, will be allocated to the employee stock ownership association first, and 18.36 million shares, or 80 percent, will be offered to the public. The bid price is 49,000 to 65,000 won. Based on the highest public offering price, the expected public offering amount is expected to be about KRW 1.4918 trillion.

SK Bioscience is a vaccine company that was established by spin-off from SK Chemicals in July 2018. It develops and sells flu vaccine, shingles vaccine, and chickenpox vaccine.


SK Bioscience’s sales and operating profit in 2019 are 183.9 billion won and 22.8 billion won, respectively. It has grown by 23.4% on an annual average for three years from 2017. The cumulative sales and operating profit for the third quarter of 2020 were 158.6 billion won and 26.8 billion won, respectively.

Ahn Jae-yong, CEO of SK Bioscience, said, “About KRW 1 trillion is expected to be secured through this public offering,” and “We are going to spend 400 billion won for facility investment, 100 billion won for platform technology acquisition, 50 to 100 billion won for glocalization that combines global and localization, and 150 to 200 billion won for R&D such as next-generation pneumococcal vaccine.”

NSP News Agency soon ki Lee Journalist
Copyright ⓒ Korea's economic news agency NSP NEWS·NSP TV. All rights reserved-Redistribution Prohibited.